MindWalk HYFT® Platform Validated by Preclinical Dengue Data
MindWalk Holdings Corp. reported preclinical dengue data that supports a computational prediction generated by its HYFT® platform. The platform identified a candidate pan-serotype structural target on the dengue virus, and subsequent animal immunization with immunogens designed on this target generated antibodies that cross-reacted with antigens of all four dengue serotypes. This clear and consistent trend was reproduced across two independent campaigns, providing MindWalk's first public evidence that its AI-driven platform can connect computational predictions to measurable biological outcomes. Future studies will assess the antibodies' functional profile, including neutralization and interaction with ADE pathways.
Key Highlights
- HYFT® platform computationally identified a pan-serotype dengue target prior to immunization.
- Immunization with immunogens designed on the predicted target elicited antibodies that cross-reacted with antigens of all four dengue serotypes.
- This cross-reactive antibody response was reproduced across two independent preclinical campaigns.
- Scrambled-sequence controls confirmed the specificity of the antibody response to the designed immunogen.
- This is MindWalk's first public evidence validating its AI platform's ability to connect computational predictions to biological outcomes.
- Dengue infects an estimated 400 million people annually across four antigenically distinct serotypes.
- Dengue envelope domain III (EDIII) sequence identity ranges from 74% to 83% across serotypes.
Price Impact
More from HYFT